A National Cancer Institute-funded case control study suggests that some current formulations of oral contraception (OCs) may increase risk of breast cancer.
A National Cancer Institute-funded case control study suggests that some current formulations of oral contraception (OCs) may increase risk of breast cancer. The authors note, however, that their findings require confirmation and should be interpreted with caution, given the established health benefits of OCs.
Published in Cancer Research, the nested case-control study led by researchers at Fred Hutchinson Cancer Research Center was among female enrollees in a large US integrated health care delivery system. Detailed information on OC use such as drug name, dosage, and duration of use was gathered from electronic pharmacy records, unlike previous studies that relied on self-report or recall.
Cases (1,102 women aged 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009) were matched to randomly sampled controls (n=21,952) from enrollment records based on age, year, enrollment length, and medical chart availability. Conditional logistic regression was used to analyze OC use information from the electronic pharmacy records.
More articles on contraception
Women who had used OCs within the prior year had an increased risk of breast cancer (OR, 1.5; 95% CI, 1.3-1.9) compared with those who had never used OCs or were former users. The association was stronger for estrogen receptor (ER)-positive disease (OR, 1.7; 95% CI, 1.3-2.1) than for ER-negative disease (OR, 1.2; 95% CI, 0.8-1.8) although it did not reach statistical significance (P=0.15). Particularly elevated risks were associated with recent use of OCs containing high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1). OCs containing low-dose estrogen were not associated with elevated risk (OR, 1.0; 95% CI, 0.6-1.7).
More research reports on breast cancer
In evaluating these findings, it should be noted that there are decades of negative studies regarding OCs and breast cancer risk and, because the results are from a case control study, they are subject to ascertainment bias. If the findings are confirmed, however, the authors said “consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks.”
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More